News

Clinical Trials Arena5d
MSD’s Enflonsia receives FDA approval for RSV prophylaxis
MSD's Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...
Fierce Pharma7d
Merck scores FDA nod for Enflonsia, setting up RSV market battle vs. Sanofi and AstraZeneca's Beyfortus
Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...
WCPO 9 News3d
FDA approves Merck’s Enflonsia to prevent RSV in infants
The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...
PharmExec6d
FDA Approves Merck’s Enflonsia to Prevent Respiratory Syncytial Virus
Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...
Medindia on MSN4d
FDA Approves ENFLONSIA to Shield Infants From RSV
In a major boost for infant health, the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA (clesrovimab-cfor) , a ...
Pulmonology Advisor3d
Enflonsia Approved for RSV Disease Prevention in Infants
The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...
New antibody shot could help protect babies from RSV
A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...
Managed Healthcare Executive6d
FDA Approves Enflonsia To Protect Infants During Their First RSV Season
Enflonsia is the first FDA-approved respiratory syncytial virus (RSV) preventative for infants, regardless of weight, according to the news release.
Merck’s Enflonsia receives FDA approval for RSV prophylaxis
Merck’s Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns ...